Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Swiss regulatory authority Swissmedic has accepted the ceftobiprole Marketing Authorization Application for review. Ceftobiprole is an investigational broad-spectrum anti-MRSA (methicillin-resistant Staphylococcus aureus) antibiotic. The intended indication of ceftobiprole is for the treatment of hospital-acquired (nosocomial) pneumonia and community-acquired pneumonia in adults.
Help employers find you! Check out all the jobs and post your resume.
